Dr Reddys Laboratories Ltd Hits Intraday High with 3.23% Surge on 10 Mar 2026

Intraday Trading Highlights and Price Movement

The stock of Dr Reddys Laboratories Ltd touched its peak at Rs 1326.5 during the trading session, representing a 3.12% rise from its previous close. By the end of the day, the stock closed with a 3.23% gain, significantly outperforming the Sensex, which recorded a modest 0.68% increase. This marks a clear reversal in the stock’s short-term trend, as it gained after two consecutive days of decline.

Notably, Dr Reddys Laboratories Ltd’s closing price remains just 3.9% shy of its 52-week high of Rs 1377.95, underscoring the stock’s proximity to its peak levels over the past year. The stock’s upward momentum was supported by its position above key moving averages, trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained buying interest throughout the session.

Comparative Performance Against Sector and Market Benchmarks

On the day, Dr Reddys Laboratories Ltd outperformed the Pharmaceuticals & Biotechnology sector by 1.83%, highlighting its relative strength within the industry. The broader market, represented by the Sensex, experienced a volatile session. After opening with a gap up of 809.57 points, the Sensex lost momentum and declined by 257.88 points to trade at 78,117.85, a 0.71% decrease. Despite this, mega-cap stocks led the market, with the Sensex still managing a 0.71% gain overall.

Over the past week, Dr Reddys Laboratories Ltd has gained 2.58%, contrasting with the Sensex’s 2.67% decline. The stock’s one-month performance stands at a 5.76% increase, while the Sensex has fallen 7.33% over the same period. This trend continues over three months, with Dr Reddys Laboratories Ltd up 6.15% versus the Sensex’s 7.46% drop. Year-to-date, the stock has risen 4.48%, outperforming the Sensex’s 8.36% loss.

Technical Indicators and Trend Analysis

Technical signals for Dr Reddys Laboratories Ltd present a mixed but cautiously optimistic picture. The weekly Moving Average Convergence Divergence (MACD) indicator remains bullish, while the monthly MACD is mildly bearish. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, indicating a neutral momentum stance.

Bollinger Bands suggest a mildly bullish trend on both weekly and monthly timeframes, supporting the recent price strength. The daily moving averages, however, are mildly bearish, reflecting some short-term caution among traders. The Know Sure Thing (KST) indicator is mildly bullish on the weekly chart but mildly bearish monthly, further underscoring the mixed technical outlook.

Other indicators such as Dow Theory and On-Balance Volume (OBV) show no definitive trend on weekly or monthly scales, suggesting that while the stock has gained today, broader directional conviction remains moderate.

Market Capitalisation and Mojo Score Update

Dr Reddys Laboratories Ltd holds a Market Cap Grade of 1, indicating its status as a large-cap entity within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score currently stands at 48.0, with a Mojo Grade of Sell, reflecting a downgrade from Hold on 9 Mar 2026. This adjustment signals a cautious stance based on the latest comprehensive evaluation metrics.

Despite the downgrade, the stock’s recent price action demonstrates resilience, with strong intraday gains and a positive trend reversal after a brief dip. This performance highlights the stock’s ability to maintain upward momentum amid broader market fluctuations.

Longer-Term Performance Context

Examining Dr Reddys Laboratories Ltd’s performance over extended periods reveals a generally positive trajectory relative to the Sensex. Over one year, the stock has appreciated by 18.57%, significantly outpacing the Sensex’s 5.37% gain. Over three years, the stock’s return of 51.03% exceeds the Sensex’s 32.06% rise, though over five years, the stock’s 47.60% gain trails the Sensex’s 52.29% increase. Over a decade, Dr Reddys Laboratories Ltd has more than doubled, with a 108.53% gain, while the Sensex has more than tripled, rising 217.15%.

This historical data underscores the stock’s capacity for sustained growth, albeit with periods of relative underperformance compared to the broader market index.

Market Environment and Sensex Overview

The broader market environment on 10 Mar 2026 was characterised by volatility. The Sensex opened with a strong gap up of 809.57 points but lost momentum to close down by 257.88 points, trading at 78,117.85, a 0.71% decline. The index is currently trading below its 50-day moving average, although the 50-day moving average remains above the 200-day moving average, indicating a longer-term positive trend despite recent weakness.

Notably, the Sensex has experienced a three-week consecutive decline, losing 5.67% over this period. Mega-cap stocks have been the primary drivers of market gains today, contrasting with the broader index’s retreat. Dr Reddys Laboratories Ltd’s outperformance relative to the Sensex and its sector highlights its relative strength amid this challenging market backdrop.

Summary of Intraday and Recent Trading Action

In summary, Dr Reddys Laboratories Ltd’s strong intraday performance on 10 Mar 2026, with a 3.23% gain and an intraday high of Rs 1326.5, marks a significant rebound after two days of declines. The stock’s ability to trade above all major moving averages and outperform both the sector and the Sensex reflects robust trading interest and positive momentum. While technical indicators present a mixed picture, the immediate price action signals a favourable shift in sentiment for the session.

Investors and market participants will note the stock’s proximity to its 52-week high and its consistent outperformance over multiple time horizons relative to the Sensex, reinforcing its status as a key player within the Pharmaceuticals & Biotechnology sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →